Amendment No. 2 to Co-Promotion Agreement between Heron Therapeutics, Inc. and CrossLink Network, LLC

Summary

Heron Therapeutics, Inc. and CrossLink Network, LLC have agreed to amend their existing Co-Promotion Agreement, originally effective January 1, 2024. This amendment, effective September 1, 2024, replaces Schedule 1 to Exhibit A of the original agreement. All other terms of the original agreement remain unchanged. The amendment clarifies that no third parties benefit from the revised schedule and confirms that any further changes must be made in writing and signed by both parties.

EX-10.2 3 hrtx-ex10_2.htm EX-10.2 EX-10.2

Exhibit 10.2

CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***].

AMENDMENT NO.2

CO-PROMOTION AGREEMENT

This Amendment No. 2 to the Co-Promotion Agreement (this “Amendment”) is made and entered into as of September 1, 2024 (the “Amendment Effective Date”) by and between Heron Therapeutics, Inc., a Delaware corporation (“Heron”) and CrossLink Network, LLC, a Georgia limited liability company (“Co-Promoter”). Heron and Co-Promoter may each be referred to herein as a “Party” and collectively as the “Parties”.

WHEREAS, the Parties entered into and are the current parties to that certain Co-Promotion Agreement with an effective date of January 1, 2024, as amended (collectively, the “Agreement”); and

WHEREAS, the Parties now desire to amend the Agreement accordingly, but only in strict accordance with, and as more particularly described in this Amendment.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by each Party to the other, the Parties mutually agree as follows:

Schedule 1 to Exhibit A. Schedule 1 to Exhibit A is hereby deleted in its entirety and replaced with the following as attached hereto and incorporated herein. For the sake of clarity, Schedule 1 to Exhibit A of this Agreement does not create any third party beneficiaries.

Entire Agreement; Amendment. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement. This Amendment taken together with the Agreement constitutes the full and complete agreement and understanding between the Parties and shall supersede all prior communications, representations, understandings or agreements, if any, whether oral or written, concerning the subject matter contained in this Amendment and the Agreement, as so amended. No provision of the Agreement as so amended may be modified, amended, waived or discharged, in whole or in part, except by a written instrument executed by the Parties. Except as expressly modified by this Amendment, the Agreement and all of its terms and conditions shall continue in full force and effect.

[Signature Page Follows]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

ACKNOWLEDGED, ACCEPTED, AND AGREED TO:


Heron Therapeutics, Inc.		Crosslink Network, LLC

/s/ Craig Collard		/s/ Richard Haury
Name: Craig Collard		Name: Richard Haury
Title: Chief Executive Officer		Title: SrVP/General Counsel
Date: November 7, 2024		Date: November 5, 2024

SCHEDULE 1 TO EXHIBIT A

[***]